FLT3 and acute myeloid leukemia: Much progress has been made in AML management, with significant advances in molecular biology and therapeutic technologies [2] including optimized chemotherapy regimens [3], refined haematopoietic stem cell transplantation strategies [4–6], and novel targeted therapies such as Bcl-2 inhibitors [7], FLT3 tyrosine kinase inhibitors [7], CD33-targeting agents [8], IDH inhibitors [7], and CAR-T-cell immunotherapy [9, 10].